Table 1.

Epidemiological and serum CA125 data for the different study groups. CA125 level was considered elevated if measuring > 35 u/ml

	Mean [range]
Ovarian cancers
Age
All patients (n = 116)	63 [20–84]
No NACT (n = 71)	61 [20–84]
NACT (n = 45)	65 [43–83]
ΒΜΙ (kg/m2)
All patients (n = 116)	26.7 [16.6–48.6]
No NACT (n = 71)	27.4 [18.2–48.6]
NACT (n = 45)	25.8 [16.6–36.4]
CA125 (u/ml)
Non-chemotherapy group (n = 71)	590 [5–8366]
Chemotherapy group, before NACT (n = 45)	2595 [62–23455]
Chemotherapy group, after NACT (n = 45)	135 [8–1104]
Benign controls (n = 307)
Age	47 [19–89]
BMI (kg/m2)	28.5 [17.3–49.8]
CA125 (u/ml)	55 [1–2627]

NACT neo-adjuvant chemotherapy